138 related articles for article (PubMed ID: 38636210)
1. Problems with NICE's severity weights.
Hausman DM
Soc Sci Med; 2024 May; 348():116833. PubMed ID: 38636210
[TBL] [Abstract][Full Text] [Related]
2. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
3. Can the NICE "end-of-life premium" be given a coherent ethical justification?
Cookson R
J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
[TBL] [Abstract][Full Text] [Related]
4. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
5. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
6. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
7. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
8. Modifying NICE's Approach to Equity Weighting.
Paulden M; McCabe C
Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
[TBL] [Abstract][Full Text] [Related]
9. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
O'Mahony JF; Paulden M
Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
[TBL] [Abstract][Full Text] [Related]
10. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves?
Drummond MF; Iglesias CP; Cooper NJ
Int J Technol Assess Health Care; 2008; 24(2):146-50. PubMed ID: 18400116
[TBL] [Abstract][Full Text] [Related]
11. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
12. Estimating 'costs' for cost-effectiveness analysis.
Miners A
Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
[TBL] [Abstract][Full Text] [Related]
13. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
[TBL] [Abstract][Full Text] [Related]
15. An analysis of NICE's 'restricted' (or 'optimized') decisions.
O'Neill P; Devlin NJ
Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
[TBL] [Abstract][Full Text] [Related]
16. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
Paulden M
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
[No Abstract] [Full Text] [Related]
17. Quality, innovation, and value for money: NICE and the British National Health Service.
Pearson SD; Rawlins MD
JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
[TBL] [Abstract][Full Text] [Related]
18. Patients' views of explicit rationing: what are the implications for health service decision-making?
Devlin N; Appleby J; Parkin D
J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
[TBL] [Abstract][Full Text] [Related]
19. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
Charlton V
Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
[TBL] [Abstract][Full Text] [Related]
20. Evidence and values: paying for end-of-life drugs in the British NHS.
Chalkidou K
Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
